The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC).
 
Mohammed M. Milhem
Honoraria - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Array BioPharma; Blueprint Medicines; Immunocore; Novartis; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Cesar Augusto Perez
Consulting or Advisory Role - Regeneron
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Maverick Therapeutics; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exicure (Inst); Kartos Therapeutics (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Maverick Therapeutics; Regeneron
 
Trisha Michel Wise-Draper
Consulting or Advisory Role - Shattuck Labs
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; bexion; Bristol-Myers Squibb; Caris Life Sciences; Lilly; Merck; Tesaro
 
Shailender Bhatia
Honoraria - Bristol-Myers Squibb; EMD Serono; EMD Serono; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; EMD Serono; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exicure (Inst); Immune Design (Inst); Incyte (Inst); Merck (Inst); NantWorks (Inst); Nektar (Inst); Novartis (Inst); OncoSec (Inst)
Travel, Accommodations, Expenses - NantWorks; Sanofi/Regeneron
 
Alice Susannah Bexon
Employment - Bexon Clinical Consulting
Leadership - SapVax; Vyriad
Stock and Other Ownership Interests - Sapience Therapeutics; Vyriad
Travel, Accommodations, Expenses - Sapience Therapeutics; Vyriad
 
Weston L Daniel
Employment - Exicure
Stock and Other Ownership Interests - Exicure
 
Steven O'Day
Honoraria - Agenus; Biothera; Bristol-Myers Squibb; ImaginAb; Merck; RadImmune
Consulting or Advisory Role - Agenus; Biothera; Bristol-Myers Squibb; ImaginAb; Merck; RadImmune
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Agenus (Inst); Amgen (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Exicure (Inst); Genocea Biosciences (Inst); Incyte (Inst); Merck (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - Agenus; Bristol-Myers Squibb; Caris MPI; ImaginAb; Merck